Zaia Annamaria, Maponi Pierluigi, Sallei Manuela, Galeazzi Roberta, Scendoni Pietro
Centre of Innovative Models and Technology for Ageing Care, Scientific Direction, IRCCS INRCA, 60121 Ancona, Italy.
School of Science and Technology, University of Camerino, 62032 Camerino, Italy.
Biomedicines. 2023 Mar 4;11(3):781. doi: 10.3390/biomedicines11030781.
An MRI method providing one parameter (TBLβ: trabecular-bone-lacunarity-parameter-β) that is sensitive to trabecular bone architecture (TBA) changes with aging and osteoporosis is under study as a new tool in the early diagnosis of bone fragility fracture. A cross-sectional and prospective observational study (LOTO: Lacunarity Of Trabecular bone in Osteoporosis) on over-50s women, at risk for bone fragility fracture, was designed to validate the method. From the baseline data, we observed that in women with prevalent vertebral fractures (VF+), TBA was differently characterized by TBLβ when osteoporosis treatment is considered. Here we verify the potential of TBLβ as an index of osteoporosis treatment efficacy. Untreated ( = 156) and treated ( = 123) women were considered to assess differences in TBLβ related to osteoporosis treatment. Prevalent VFs were found in 31% of subjects, 63% of which were under osteoporosis medications. The results show that TBLβ discriminates between VF+ and VF- patients ( = 0.004). This result is mostly stressed in untreated subjects. Treatment, drug therapy in particular (89% Bisphosphonates), significantly counteracts the difference between VF+ and VF- within and between groups: TBLβ values in treated patients are comparable to untreated VF- and statistically higher than untreated VF+ ( = 0.014) ones. These results highlight the potential role of TBLβ as an index of treatment efficacy.
一种磁共振成像（MRI）方法可提供一个对小梁骨结构（TBA）随衰老和骨质疏松症变化敏感的参数（TBLβ：小梁骨腔隙率参数-β），目前正在作为骨脆性骨折早期诊断的新工具进行研究。一项针对有骨脆性骨折风险的50岁以上女性的横断面前瞻性观察研究（LOTO：骨质疏松症中小梁骨的腔隙率）旨在验证该方法。从基线数据中，我们观察到，在患有椎体骨折（VF+）的女性中，考虑骨质疏松症治疗时，TBA由TBLβ呈现出不同的特征。在此，我们验证TBLβ作为骨质疏松症治疗疗效指标的潜力。将未治疗（n = 156）和已治疗（n = 123）的女性纳入研究，以评估与骨质疏松症治疗相关的TBLβ差异。在31%的受试者中发现了既往椎体骨折，其中63%正在接受骨质疏松症药物治疗。结果表明，TBLβ能够区分VF+和VF-患者（P = 0.004）。这一结果在未治疗的受试者中最为显著。治疗，尤其是药物治疗（89%为双膦酸盐类药物），显著抵消了组内和组间VF+和VF-之间的差异：治疗患者的TBLβ值与未治疗的VF-患者相当，且在统计学上高于未治疗的VF+患者（P = 0.014）。这些结果突出了TBLβ作为治疗疗效指标的潜在作用。
